(2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide

C60H77F3N10O8 — CID 166145466

IUPAC(2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide
SMILESCO[C@@H](C)c1ncc(N2CCN3CCOC[C@@H]3C2)cc1-c1c2c3cc(ccc3n1CC(F)(F)F)-c1cccc(c1)C[C@H](NC(=O)[C@H](C1CCCC1)N1CCOC3(CN(C(=O)[C@H]4CN4)C3)C1)C(=O)N1CCC[C@H](N1)C(=O)OCC(C)(C)C2
InChIInChI=1S/C60H77F3N10O8/c1-37(78-4)51-45(26-42(28-65-51)69-18-17-68-19-21-79-31-43(68)30-69)53-46-27-58(2,3)36-80-57(77)47-13-8-16-73(67-47)56(76)48(24-38-9-7-12-40(23-38)41-14-15-50(44(46)25-41)72(53)35-60(61,62)63)66-54(74)52(39-10-5-6-11-39)70-20-22-81-59(32-70)33-71(34-59)55(75)49-29-64-49/h7,9,12,14-15,23,25-26,28,37,39,43,47-49,52,64,67H,5-6,8,10-11,13,16-22,24,27,29-36H2,1-4H3,(H,66,74)/t37-,43-,47-,48-,49+,52-/m0/s1
InChIKeyVIRQEKBHEYXCKX-HCFMSRMRSA-N
MW1123.33 g/mol
LogP5.25
Rot. Bonds10

About (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide

(2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide (PubChem CID 166145466) has the molecular formula C60H77F3N10O8 and a molecular weight of 1123.33 g/mol. Its IUPAC name is (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide.

Molecular Properties

Compound Name(2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide
PubChem CID166145466
Molecular FormulaC60H77F3N10O8
Molecular Weight1123.33 g/mol
Exact Mass1122.59
IUPAC Name(2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide
SMILESCO[C@@H](C)c1ncc(N2CCN3CCOC[C@@H]3C2)cc1-c1c2c3cc(ccc3n1CC(F)(F)F)-c1cccc(c1)C[C@H](NC(=O)[C@H](C1CCCC1)N1CCOC3(CN(C(=O)[C@H]4CN4)C3)C1)C(=O)N1CCC[C@H](N1)C(=O)OCC(C)(C)C2
InChIInChI=1S/C60H77F3N10O8/c1-37(78-4)51-45(26-42(28-65-51)69-18-17-68-19-21-79-31-43(68)30-69)53-46-27-58(2,3)36-80-57(77)47-13-8-16-73(67-47)56(76)48(24-38-9-7-12-40(23-38)41-14-15-50(44(46)25-41)72(53)35-60(61,62)63)66-54(74)52(39-10-5-6-11-39)70-20-22-81-59(32-70)33-71(34-59)55(75)49-29-64-49/h7,9,12,14-15,23,25-26,28,37,39,43,47-49,52,64,67H,5-6,8,10-11,13,16-22,24,27,29-36H2,1-4H3,(H,66,74)/t37-,43-,47-,48-,49+,52-/m0/s1
InChIKeyVIRQEKBHEYXCKX-HCFMSRMRSA-N
XLogP5.25
TPSA185.22 Ų
H-Bond Donors3
H-Bond Acceptors15
Rotatable Bonds10
Heavy Atoms81
Complexity

Lipinski Rule of Five

3 violations

RuleValue
MW ≤ 5001123.33
LogP ≤ 55.25
H-Bond Donors ≤ 53
H-Bond Acceptors ≤ 1015

Computed Properties (RDKit)

Structural Alerts{'alert_name': 'Three-membered_heterocycle', 'substructure': 'N/A'}

Analyze (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Related Compounds

Frequently Asked Questions

What is the IUPAC name of (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide?
The IUPAC name of (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide (CID 166145466) is (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide.
What is the SMILES notation for (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide?
The canonical SMILES for (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide is CO[C@@H](C)c1ncc(N2CCN3CCOC[C@@H]3C2)cc1-c1c2c3cc(ccc3n1CC(F)(F)F)-c1cccc(c1)C[C@H](NC(=O)[C@H](C1CCCC1)N1CCOC3(CN(C(=O)[C@H]4CN4)C3)C1)C(=O)N1CCC[C@H](N1)C(=O)OCC(C)(C)C2.
What is the InChIKey of (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide?
The InChIKey is VIRQEKBHEYXCKX-HCFMSRMRSA-N. The full InChI is InChI=1S/C60H77F3N10O8/c1-37(78-4)51-45(26-42(28-65-51)69-18-17-68-19-21-79-31-43(68)30-69)53-46-27-58(2,3)36-80-57(77)47-13-8-16-73(67-47)56(76)48(24-38-9-7-12-40(23-38)41-14-15-50(44(46)25-41)72(53)35-60(61,62)63)66-54(74)52(39-10-5-6-11-39)70-20-22-81-59(32-70)33-71(34-59)55(75)49-29-64-49/h7,9,12,14-15,23,25-26,28,37,39,43,47-49,52,64,67H,5-6,8,10-11,13,16-22,24,27,29-36H2,1-4H3,(H,66,74)/t37-,43-,47-,48-,49+,52-/m0/s1.
What are the key properties of (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide?
(2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide has a molecular weight of 1123.33 g/mol, XLogP of 5.25, 10 rotatable bonds, 3 hydrogen bond donors, and 15 hydrogen bond acceptors.
Where does this data come from?
All data for (2S)-N-[(8S,14S)-21-[5-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23(27),24-heptaen-8-yl]-2-[2-[(2R)-aziridine-2-carbonyl]-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl]-2-cyclopentylacetamide is sourced from PubChem (CID 166145466), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).